Literature DB >> 6503612

Tolerance to an anticholinergic agent is paralleled by increased binding to muscarinic receptors in rat brain and increased behavioral response to a centrally active cholinomimetic.

R Majocha, R J Baldessarini.   

Abstract

Pretreatment of rats with agents with strong antimuscarinic activity in the CNS (scopolamine, benztropine, trihexyphenidyl, amitriptyline, and thioridazine) but not their inactive congeners (desipramine, fluphenazine, or haloperidol) led to significant increases in the maximum apparent density of binding sites for 3H-QNB in cerebral cortical or striatal membranes. The dopamine agonist bromocriptine induced a similar effect that was blocked by haloperidol in striatum. None of these treatments altered the apparent affinity of the test ligand. Tolerance to the behavioral activating action of scopolamine developed over two weeks of daily treatment. This change was paralleled by an increase in 3H-QNB binding in cerebral cortex which was dependent on the dose and duration of treatment with scopolamine and persisted for a week following two weeks of treatment. Scopolamine pretreatment led to a significant increase in basal, spontaneous motor activity in the rat, but also to a marked increase in the motor-inhibitory actions of the centrally active muscarinic agonist pilocarpine. These results add to the impression that decreased availability of ACh agonists can significantly increase the availability and functional activity of central muscarinic ACh receptors to reflect "disuse supersensitivity."

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6503612     DOI: 10.1016/0024-3205(84)90466-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Behavioural tolerance to arecoline in rats: cross-tolerance to oxotremorine and prevention by pretreatment with atropine.

Authors:  D H Overstreet; O S Jamal
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  Genetic and pharmacological models of cholinergic supersensitivity and affective disorders.

Authors:  D H Overstreet; R W Russell; A D Crocker; J C Gillin; D S Janowsky
Journal:  Experientia       Date:  1988-06-15

3.  Cholinergic neurotransmission seems not to be involved in depression but possibly in personality.

Authors:  J Fritze; M Lanczik; E Sofic; M Struck; P Riederer
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

4.  Dose-dependent effects of repeated ketamine administration on muscarinic acetylcholine receptors in the mouse forebrain.

Authors:  Shinichiro Hitomi; Toshihito Morita; Shigeru Saito; Yoshitaka Uchihashi
Journal:  J Anesth       Date:  1995-09       Impact factor: 2.078

5.  Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.

Authors:  T Sunderland; G Esposito; S E Molchan; R Coppola; D W Jones; J Gorey; J T Little; M Bahro; D R Weinberger
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

6.  Pharmacological adaptations and muscarinic receptor plasticity in hypothalamus of senescent rats treated chronically with cholinergic drugs.

Authors:  N W Pedigo
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Repeated ketamine administration produces up-regulation of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice.

Authors:  T Morita; S Hitomi; S Saito; T Fujita; Y Uchihashi; H Kuribara
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

8.  Antioxidants Reverse the Changes in the Cholinergic System Caused by L-Tyrosine Administration in Rats.

Authors:  Lara M Gomes; Giselli Scaini; Milena Carvalho-Silva; Maria L Gomes; Fernanda Malgarin; Luiza W Kist; Maurício R Bogo; Eduardo Pacheco Rico; Alexandra I Zugno; Pedro F P Deroza; Gislaine Z Réus; Airam B de Moura; João Quevedo; Gustavo C Ferreira; Patrícia F Schuck; Emilio L Streck
Journal:  Neurotox Res       Date:  2018-02-07       Impact factor: 3.911

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.